Ibuprofen

Articles · Medicine Compliance Aid Stability · Lactation Safety Information · New Medicines ·
38268001

Articles

Medicine Compliance Aid Stability

generic · Wockhardt UK Ltd

Wockhardt UK Ltd
generic
Tablets 400mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture
12th August 2015

Brufen Retard · Abbott Healthcare Products Ltd

Abbott Healthcare Products Ltd
Brufen Retard
Tablets 800mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from light
12th August 2015

Brufen · Abbott Healthcare Products Ltd

Abbott Healthcare Products Ltd
Brufen
Tablets 200mg, 400mg, 600mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from light
12th August 2015

Lactation Safety Information

Extensive experience of safe use in breastfeeding
Limited published evidence of safety
No adverse effects reported in breastfed infants
Negligible amounts in breast milk
24th September 2020

Topical

Topical
Negligible milk levels anticipated as systemic absorption from topical formulations is low
Follow normal precautions for topical medicines (see summary)
24th September 2020

New Medicines

Acute moderate pain - short-term treatment (IV infusion)

Information

New formulation
Dr Reddy's Laboratories
Not known

Development and Regulatory status

Approved (Licensed)
Launched
None
Sep 19 · Ibuprofen is licensed for use in adults for the short-term symptomatic treatment of acute moderate pain, when administration by intravenous route is clinically justified when other routes of administration are not possible [1].
Sep 19 · Licensed in the UK. Company plans to launch in 2020 [1,2].

Category

Intravenous infusion formulation of the NSAID, ibuprofen
Of people who undergo surgery, almost 60% experience severe pain in the post‑operative period [3].
Acute moderate pain - short-term treatment (IV infusion)
Intravenous infusion

Evidence based evaluations

Acute moderate pain and fever in adults - short-term treatment (IV infusion)

Information

New formulation
B Braun Medical
Not known

Development and Regulatory status

Licensed but not launched
Launched
Not known
Apr 17 · Ibuprofen is licensed for use in adults for the short-term symptomatic treatment of acute moderate pain, and for the short-term symptomatic treatment of fever, when administration by intravenous route is clinically justified when other routes of administration are not possible [1].
Apr 17 · Date of first authorisation in the UK. Company plans to launch Q1 2020 [1,2].

Category

Intravenous infusion formulation of the NSAID, ibuprofen. Available as 400mg and 600mg infusions.
Of people who undergo surgery, almost 60% experience severe pain in the post‑operative period [4].
Acute moderate pain and fever in adults - short-term treatment (IV infusion)
Intravenous infusion

Evidence based evaluations

Acute moderate pain and fever in children and adolescents weighing 20kg and over, and aged 6 years and over - short-term treatment (IV infusion)

Information

Licence extension / variation
B Braun Medical
Not Known

Development and Regulatory status

Approved (Licensed)
None
None
Jan 20 · Ibuprofen is licensed for use in adolescents and children from 20 kg bodyweight and 6 years of age and above for the short-term symptomatic treatment of acute moderate pain and for the short-term symptomatic treatment of fever, when administration by intravenous route is clinically justified, when other routes of administration are not possible [1].

Category

Intravenous infusion formulation of the NSAID, ibuprofen. Available as a 200mg infusion.
Of people who undergo surgery, almost 60% experience severe pain in the post‑operative period [2].
Acute moderate pain and fever in children and adolescents weighing 20kg and over, and aged 6 years and over - short-term treatment (IV infusion)
Intravenous infusion

Evidence based evaluations